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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
barley beta-glucans and lowering of blood cholesterol and reduced risk of 
(coronary) heart disease pursuant to Article 14 of Regulation (EC) 
No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Cargill Incorporated submitted pursuant to Article 14 of Regulation (EC) No 
1924/2006 via the Competent Authority of Belgium, the Panel on Dietetic Products, Nutrition and Allergies was 
asked to deliver an opinion on the scientific substantiation of a health claim related to barley beta-glucans and 
lowering of blood cholesterol and reduced risk of (coronary) heart disease, referring to disease risk reduction and 
including a request for the protection of proprietary data. The food constituent that is the subject of the health 
claim, barley beta-glucans, is sufficiently characterised. Lowering blood LDL-cholesterol concentration is a 
beneficial physiological effect by decreasing the risk of coronary heart disease. The applicant identified a total of 
16 references as being pertinent to the health claim. These references comprised three meta-analyses, 10 human 
intervention studies, two animal studies and one mechanistic study. In weighing the evidence, the Panel took into 
account that one meta-analysis including 11 RCTs and one additional RCT which investigated the effects of 
barley beta-glucans at doses of at least 3 g/day showed a decrease in total and LDL-cholesterol concentrations in 
both normo- and hypercholesterolaemic subjects, and that the mechanism by which barley beta-glucans could 
exert the claimed effect is biologically plausible and supported by the animal studies provided. The Panel 
concludes that a cause and effect relationship has been established between the consumption of barley beta-
glucans and the lowering of blood LDL-cholesterol concentrations. The following wording reflects the scientific 
evidence: “Barley beta-glucans have been shown to lower/reduce blood cholesterol. High cholesterol is a risk 
factor in the development of coronary heart disease”. At least 3 g of barley beta-glucans should be consumed per 
day in order to obtain the claimed effect. The target population is adults who want to lower their blood 
cholesterol concentrations. © European Food Safety Authority, 2011 
KEY WORDS 
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SUMMARY 
Following an application from Cargill Incorporated submitted pursuant to Article 14 of Regulation 
(EC) No 1924/2006 via the Competent Authority of Belgium, the Panel on Dietetic Products, 
Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of a health 
claim related to barley beta-glucans and lowering of blood cholesterol and reduced risk of (coronary) 
heart disease. 
The scope of the application was proposed to fall under a health claim referring to disease risk 
reduction and including a request for the protection of proprietary data. 
The food constituent that is the subject of the health claim is barley beta-glucans. Beta-glucans are 
non-starch polysaccharides composed of glucose molecules in long linear polymers. Beta-glucans 
occur naturally in barley and are measurable in foods by established methods. This opinion applies to 
barley beta-glucans naturally present in foods and to those forms added to foods. The Panel considers 
that the food constituent, barley beta-glucans, which is the subject of the health claim, is sufficiently 
characterised. 
The claimed effect is “lowering/reduction of blood cholesterol, which may reduce the risk of 
(coronary) heart disease”. The target population proposed by the applicant is adults with normal or 
mildly elevated blood cholesterol concentrations. The Panel considers that lowering blood LDL-
cholesterol concentration is a beneficial physiological effect by decreasing the risk of coronary heart 
disease. 
The Panel has already issued an opinion on beta-glucans from various sources, including barley, and 
maintenance of normal blood cholesterol concentrations, pursuant to Article 13(1) of Regulation (EC) 
No 1924/2006, with a favourable outcome. The Panel has also issued an opinion on barley 
beta-glucans and reduction of blood cholesterol concentrations, which may reduce the risk of 
(coronary) heart disease, pursuant to Article 14 of Regulation (EC) No 1924/2006, with a favourable 
outcome. 
The applicant identified a total of 16 references as being pertinent to the health claim. These 
references comprised three meta-analyses, 10 human intervention studies, two animal studies and one 
mechanistic study. 
The information provided for one of the studies was insufficient to allow a scientific evaluation by the 
Panel. The mechanistic study was an acute trial concerned with the production of short chain fatty 
acids following the consumption of cereal-based meals. The Panel considers that no conclusions can 
be drawn from these two studies for the scientific substantiation of the claim. 
The first meta-analysis comprised 11 studies (17 treatment arms) which included a total of 591 
subjects. Seven studies had a cross-over design and four had a parallel design. The duration of the 
intervention lasted from 4 to 12 weeks (mean 5.2 weeks) and 10–62 subjects were enrolled in the 
studies. Study populations were both normo- and hypercholesterolaemic, with mean blood cholesterol 
ranges from 3.6 to 8.6 mmol/L. The mean age ranged from 20 to 63 years. Mean baseline body mass 
index ranged from 19 to 35 kg/m
2
. The estimated daily consumption of barley beta-glucans ranged 
from 3 to 12 g, with a median intervention dose of 5 g/day. The sources of barley beta-glucans 
included barley flour, barley flakes, pearled barley, and barley bran. Most control groups received 
comparable products based on wheat or rice. Overall, barley beta-glucans lowered total and LDL-
cholesterol concentrations by 0.30 mmol/L (95 % CI: 0.39 to 0.21, p<0.00001) and 0.27 mmol/L 
(95 % CI: 0.34 to 0.20, p<0.00001), respectively. HDL-cholesterol concentrations were not affected. 
The second meta-analysis included eight studies, seven of which were already included in the meta-
analysis above. The additional study was a randomised, parallel, 30-day intervention trial in 
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79 hypercholesterolaemic subjects. The results from this meta-analysis were similar to those obtained 
in the first meta-analysis. Barley beta-glucans lowered total and LDL-cholesterol concentrations by 
0.35 mmol/L (95 % CI: 0.48 to 0.21, p<0.05) and by 0.26 mmol/L (95 % CI: 0.36 to 0.16, p<0.05), 
respectively. Other blood lipid parameters were not affected. To address publication bias, visual 
inspection of funnel plots, Egger's weighted regression statistics, and the trim and fill method were 
applied. When potentially missing studies (i.e. unpublished negative studies) were taken into account, 
barley beta-glucans still had a significant, albeit reduced, effect on total and LDL-cholesterol 
concentrations. 
The applicant submitted a third meta-analysis with a total of eight studies which were already taken 
into account in the first meta-analysis above. The Panel notes that this third meta-analysis does not 
provide additional information for the scientific substantiation of the claim. 
In a randomised controlled cross-over trial, 24 mildly hypercholesterolaemic men consumed a barley 
beta-glucan enriched diet (6 g barley beta-glucans per day) or a rice bran-enriched control diet for 
4 weeks each (with a 3-week washout in between) after a 3-week run-in period. Compared to the rice-
bran diet, the barley beta-glucan diet induced a significant decrease in total and LDL-cholesterol 
concentrations of 0.34 mmol/L (95 % CI: 0.47 to 0.20, p<0.001) and 0.21 mmol/L (95 % CI: 0.40 to 
0.02, p=0.033), respectively. No effects were observed on other blood lipid parameters. 
Two animal studies in Syrian golden hamsters compared the efficiency of beta-glucans of different 
sources (barley and oat), and of barley beta-glucans of varying molecular weight (high and low MW), 
respectively. The studies found that irrespective of the source or the molecular weight, beta-glucans 
were effective in lowering blood total and LDL-cholesterol concentrations. Furthermore, both studies 
showed increases in the concentrations of faecal total neutral sterols following consumption of the 
various beta-glucans. The Panel considers that these studies are supportive of the effect of barley 
beta-glucans. 
The cholesterol-lowering effect of barley beta-glucans is considered to depend on increased viscosity 
that reduces the reabsorption of bile acids and increases both the synthesis of bile acids from 
cholesterol as well as the faecal excretion of neutral sterols. Viscosity in the small intestine is 
determined by the concentration, molecular weight and solubility of the barley beta-glucans. 
In weighing the evidence, the Panel took into account that one meta-analysis including 11 RCTs, and 
one additional RCT, which investigated the effects of barley beta-glucans at doses of at least 3 g/day 
showed a decrease in total and LDL-cholesterol concentrations in both normo- and hyper-
cholesterolaemic subjects, and that the mechanism by which barley beta-glucans could exert the 
claimed effect is biologically plausible and supported by the animal studies provided. 
The Panel concludes that a cause and effect relationship has been established between the 
consumption of barley beta-glucans and the lowering of blood LDL-cholesterol concentrations. 
The Panel considers that the following wording reflects the scientific evidence: “Barley beta-glucans 
have been shown to lower/reduce blood cholesterol. High cholesterol is a risk factor in the 
development of coronary heart disease”. 
The Panel considers that at least 3 g of barley beta-glucans should be consumed per day in order to 
obtain the claimed effect. This amount can reasonably be consumed as part of a balanced diet. The 
target population is adults who want to lower their blood cholesterol concentrations. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14 to 17 of this 
Regulation lay down provisions for the authorisation and subsequent inclusion of reduction of disease 
risk claims and claims referring to children’s development and health in a Community list of 
permitted claims. 
According to Article 15 of this Regulation, an application for authorisation shall be submitted by the 
applicant to the national competent authority of a Member State, which will make the application and 
any supplementary information supplied by the applicant available to the European Food Safety 
Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 10/06/2011. 
 The scope of the application was proposed to fall under a health claim referring to disease 
risk reduction and including a request for the protection of proprietary data. 
 On 07/07/2011, during the validation process of the application, EFSA sent a request to the 
applicant to provide additional information. 
 The applicant provided the requested information on 27/07/2011. 
 The scientific evaluation procedure started on 10/08/2011. 
 During its meeting on 23/11/2011, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to barley beta-
glucans and the lowering of blood LDL-cholesterol concentrations. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: barley beta-glucans and lowering 
of blood cholesterol and reduced risk of (coronary) heart disease. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of barley beta-glucans, a positive assessment of its safety, nor a decision on whether barley beta-
glucans are, or are not, classified as a foodstuff. It should be noted that such an assessment is not 
foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 17 of Regulation (EC) No 1924/2006. 
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Cargill Incorporated, acting through Cargill Health and Nutrition, 
c/o Cargill R&D Centre Europe, Havenstraat 84, B-1800 Vilvoorde, Belgium. 
The applicant claimed proprietary rights for the meta-analysis conducted by Harland JI (2011, 
unpublished) and for information pertaining to the production process of barley betafiber (Barliv
TM
). 
Food/constituent as stated by the applicant 
According to the applicant, barley beta-glucans, which are soluble cereal fibres. 
Health relationship as claimed by the applicant 
According to the applicant, consuming at least 3 g of barley beta-glucans per day helps reduce LDL- 
and total cholesterol. LDL-cholesterol is a risk factor for coronary heart disease (CHD), so reducing 
this risk factor within a healthy diet and lifestyle can help to lower the overall risk of developing heart 
disease. 
Wording of the health claim as proposed by the applicant 
The applicant proposed the following wording for the health claim: “Barley beta-glucan has been 
shown to lower/reduce blood cholesterol. Blood cholesterol lowering may reduce the risk of 
(coronary) heart disease”. 
Specific conditions of use as proposed by the applicant 
According to the applicant, to bear the claim: 
 Foods should provide at least 3 g/day of beta-glucans from barley, barley bran, or from 
mixtures of non-processed or minimally processed barley beta-glucans in one or more 
servings. 
 A minimum of 0.75 g of beta-glucans per serving is recommended, or one-fourth of the 3 g 
daily amount specified above, to assist consumers to choose foods to suit their diet. 
 The weight-average molecular weight of the barley beta-glucans that are the subject of this 
application varies between 100 and 2000 kDa. 
 The label ingredient list should refer to its barley origin in compliance with Commission 
Directive relating to the labelling, presentation and advertising of foodstuffs (2000/13/EC 
and, as amended by 2007/68/EC). 
The target population proposed by the applicant is adults with normal or mildly elevated blood 
cholesterol concentrations. 
Similar claims as proposed/authorised by other entities 
The US Food and Drug Administration (FDA, 2005, 2008) has already approved a health claim for 
barley beta-glucans which is similar to the one proposed in this application. Barley beta-fiber was 
included as an eligible source in 2008, based on the evidence provided by Keenan et al. (2007). 
In 2006, the Swedish Code of Practice extended its claim about certain types of dietary fibre and 
cholesterol-lowering effects to barley fibres (Åman, 2006). 
Barley beta-glucans and lowering of blood cholesterol and  
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ASSESSMENT 
1. Characterisation of the food/constituent 
The food constituent that is the subject of the health claim is barley beta-glucans, which are soluble 
fibres present in barley (Hordeum vulgare L.). Beta-glucans are non-starch polysaccharides composed 
of glucose molecules in long linear polymers consisting in blocks of 2-4 glucose units linked by β-
(1→4) bonds, separated generally by a single glucose molecule with a β-(1→3) link, leading to an 
approximate distribution of 70 % to 30 % for the two types of linkages. The molecular weight (MW) 
varies between 50 and 2000 kDa. The mixed linkages are important for the physical properties, such 
as solubility and viscosity. Viscosity is a function of the concentration of dissolved beta-glucans and 
of its molecular weight (Wood et al., 2000), and further depends on differences in raw materials, 
processing and methods of determination. Beta-glucans occur naturally in barley (4-7 %) and are 
measurable in foods by established methods. This opinion applies to barley beta-glucans naturally 
present in foods, and to those forms added to foods. 
The Panel considers that the food constituent, barley beta-glucans, which is the subject of the health 
claim, is sufficiently characterised. 
2. Relevance of the claimed effect to human health 
The claimed effect is “lowering/reduction of blood cholesterol, which may reduce the risk of 
(coronary) heart disease”. The target population proposed by the applicant is adults with normal or 
mildly elevated blood cholesterol concentrations. 
Coronary heart disease (CHD) is a leading cause of mortality and morbidity in European populations, 
with over 1.9 million deaths in the European Union and over 4.35 million deaths in Europe each year 
(Pedersen et al., 2005). Elevated blood cholesterol is an important modifiable risk factor in the 
development of CHD (WHO, 2002a, b). 
It has been shown that blood cholesterol concentrations can be decreased by drugs, and by dietary and 
lifestyle changes (Denke, 2005; Gordon, 2000; Ornish et al., 1998; van Horn et al., 2008). 
The Panel considers that lowering blood LDL-cholesterol concentrations is a beneficial physiological 
effect by decreasing the risk of coronary heart disease. 
3. Scientific substantiation of the claimed effect 
The Panel has already issued an opinion on beta-glucans from various sources, including barley, and 
maintenance of normal blood cholesterol concentrations, pursuant to Article 13(1) of Regulation (EC) 
No 1924/2006 (EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2009). On the basis 
of the studies provided for oat beta-glucans, and of eight studies provided for barley beta-glucans 
(Behall et al., 2004a, b; Biörklund et al., 2005; Keenan et al., 2007; Keogh et al., 2003; McIntosh et 
al., 1991; Newman et al., 1989; Shimizu et al., 2008), the Panel concluded that a cause and effect 
relationship had been established between the consumption of beta-glucans and the maintenance of 
normal blood cholesterol concentrations. Six of the studies conducted with barley beta-glucans 
(Behall et al., 2004a, b; Keenan et al., 2007; McIntosh et al., 1991; Newman et al., 1989; Shimizu et 
al., 2008) showed significant lowering of LDL-cholesterol concentrations, whereas two studies did 
not (Biörklund et al., 2005; Keogh et al., 2003). 
The Panel has also issued an opinion on barley beta-glucans and reduction of blood cholesterol 
concentrations, which may reduce the risk of (coronary) heart disease, pursuant to Article 14 of 
Regulation (EC) No 1924/2006, with a favourable outcome (EFSA Panel on Dietetic Products, 
Nutrition and Allergies (NDA), 2011). 
Barley beta-glucans and lowering of blood cholesterol and  
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The applicant performed a literature search in Medline and Embase (from 1990 until February 2011) 
using the search terms “barley beta-glucan” and “cholesterol or blood lipids”. The search was 
confined to human studies and was complemented by hand searching using reference lists in 
identified publications. Studies were included if they were well designed (i.e. suitable controls, no 
significant weight gain/loss during the study, no significant differences in primary outcome measures 
at baseline between intervention and control groups), were conducted in healthy populations with 
normal or mildly elevated blood cholesterol concentrations, and used at least 3 g of barley beta-
glucans per day for the intervention. 
The applicant identified a total of 16 references as being pertinent to the health claim. These 
references comprised three meta-analyses (including one unpublished meta-analysis claimed as 
proprietary by the applicant), 10 human intervention studies (including one unpublished human 
study), two animal studies and one mechanistic study. 
The information provided for one of the studies (Pins et al., unpublished, abstract only) was 
insufficient to allow a scientific evaluation by the Panel. The mechanistic study (Nilsson et al., 2010) 
was an acute trial concerned with the production of short chain fatty acids following the consumption 
of cereal-based meals. The Panel considers that no conclusions can be drawn from these two studies 
for the scientific substantiation of the claim. 
The three meta-analyses (AbuMweis et al., 2010; Talati et al., 2009; Harland, 2011, unpublished and 
claimed as proprietary by the applicant) considered all but one (Rondanelli et al., 2011) of the 
remaining individual randomised controlled trials (RCTs) which the applicant provided for the 
scientific substantiation of the claim. 
The first meta-analysis (AbuMweis et al., 2010) comprised 11 studies (17 treatment arms) published 
between 1989 and 2008, and which included a total of 591 subjects (Behall et al., 2004a, b; Biörklund 
et al., 2005; Keenan et al., 2007; Keogh et al., 2003; Li et al., 2003; McIntosh et al., 1991; Newman et 
al., 1989; No authors listed, 2005, unpublished clinical study report; Shimizu et al., 2008; Sundberg, 
2008). Seven studies had a cross-over design and four had a parallel design. The duration of the 
intervention lasted from 4 to 12 weeks (mean 5.2 weeks) and study size ranged from 10 to 62 subjects. 
Study populations were both normo- and hypercholesterolaemic (mean blood cholesterol 
concentrations 3.6 to 8.6 mmol/L), the mean age ranged from 20-63 years and the mean body mass 
index (BMI) from 19-35 kg/m
2
. Five studies recruited only males and one study recruited only 
females. The estimated daily consumption of barley beta-glucans ranged from 3 to 12 g, with a 
median intervention dose of 5 g/day. The sources of barley beta-glucans included barley flour, barley 
flakes, pearled barley and barley bran which were consumed as breakfast cereals, biscuits, bread, 
pancakes, muffins, tabbouleh, steamed grains, powders, juice/drinks and a low MW gelled form. Most 
control groups received comparable products based on wheat or rice. In five studies, subjects 
consumed their habitual diet, and in two studies, an American Heart Association Step I diet. Two 
other studies were controlled feeding trials with typical Japanese and Western diets. In one study 
subjects were given instructions to follow a low saturated and low trans fat diet. The primary outcome 
of this meta-analysis was to quantify the effect of beta-glucans from barley on total and LDL-
cholesterol concentrations. Estimates of the pooled treatment effect size and 95 % confidence 
intervals (CI) were calculated using both fixed effect and random effects models. Overall, barley beta-
glucans lowered total and LDL-cholesterol concentrations by 0.30 mmol/L (95 % CI: 0.39 to 0.21, 
p<0.00001) and by 0.27 mmol/L (95 % CI: 0.34 to 0.20, p<0.00001), respectively. The ingestion of 
barley beta-glucans did not affect HDL-cholesterol concentrations. The cholesterol-lowering effect of 
beta-glucans from barley was apparently independent of baseline cholesterol concentrations, type of 
intervention and food matrix. High doses of barley beta-glucans (>7 g/day) did not appear to have a 
greater effect on blood cholesterol than modest consumption (3-5 g/day). In one study, consumption 
of either high or low MW barley beta-glucans at doses of 3 and 5 g/day for six weeks significantly 
decreased LDL-cholesterol concentrations relative to control (Keenan et al., 2007). However, the MW 
of beta-glucans was not reported in the majority of studies and therefore it was not possible to assess 
Barley beta-glucans and lowering of blood cholesterol and  
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the impact of MW on the cholesterol-lowering effect of barley beta-glucans in these studies. Funnel 
plots were used to assess publication bias. Their slightly asymmetrical appearance indicated that small 
negative studies might have remained unpublished. The Panel notes that nine out of the 11 studies 
considered in the meta-analysis reported a significant effect of barley-beta glucans on total and LDL-
cholesterol concentrations. 
The second meta-analysis (Talati et al., 2009) included eight studies (13 treatment arms, 
391 subjects), seven of which (Biörklund et al., 2005; Keenan et al., 2007; Keogh et al., 2003; Li et 
al., 2003; McIntosh et al., 1991; Newman et al., 1989; Shimizu et al., 2008) were already included in 
the meta-analysis by AbuMweis et al. (2010). The additional study (Lupton et al., 1994) was a 
randomised, parallel, 30-day intervention in 79 hypercholesterolaemic subjects. The results from this 
meta-analysis were similar to those obtained by AbuMweis et al. (2010). Barley beta-glucans lowered 
total and LDL-cholesterol concentrations by 0.35 mmol/L (95 % CI: 0.48 to 0.21, p<0.05) and by 
0.26 mmol/L (95 % CI: 0.36 to 0.16, p<0.05), respectively. Other blood lipid parameters (HDL-
cholesterol, triglycerides) were not affected. To address publication bias, visual inspection of funnel 
plots, Egger's weighted regression statistics, and the trim and fill method were applied. When 
potentially missing studies (i.e. unpublished negative studies) were taken into account, barley beta-
glucans still had a significant, albeit reduced, effect on total and LDL-cholesterol concentrations. 
The applicant submitted a third meta-analysis (Harland, 2011, unpublished and claimed as proprietary 
by the applicant) which considered eight studies (Behall et al., 2004a, b; Keenan et al., 2007; Keogh 
et al., 2003; Li et al., 2003; McIntosh et al., 1991; Newman et al., 1989; Shimizu et al., 2008) already 
taken into account in the meta-analysis by AbuMweis et al. (2010). The Panel notes that this meta-
analysis does not provide additional information to the meta-analysis by AbuMweis et al. (2010) for 
the scientific substantiation of the claim. 
One human intervention study (Rondanelli et al., 2011) which was not available at the time the three 
meta-analyses above were conducted was also provided by the applicant. In this randomised 
controlled cross-over trial, 24 mildly hypercholesterolaemic men (mean age 50.3±5.3 years) 
consumed a barley beta-glucan-enriched diet or a rice bran-enriched control diet for four weeks each 
(with a three-week wash-out in between) after a three-week run-in period on a Step 1 American Heart 
Association diet containing rice bran enriched foods (providing 19.7 g/day total dietary fibre, 
including 7 g/day soluble fibre). The barley beta-glucan diet provided 39.3 g/day total dietary fibre, of 
which 13.7 g/day was soluble fibre and 6 g/day of this was barley beta-glucans from a dry, processed, 
“high” (but undeclared) molecular weight concentrate included in various foods. The rice bran-
enriched control diet provided 45.7 g/day total fibre, of which 10.4 g/day was soluble fibre. A 
significant decrease in total cholesterol (-0.54 mmol/L, 95 % CI: -0.75 to -0.33, p<0.001) and LDL-
cholesterol (-0.53 mmol/L, 95 % CI: -0.79 to -0.26, p<0.001) was observed during the run-in period. 
The treatment effect of the barley beta-glucan and the rice diets was presented as the mean difference 
between final values (95 % CI) adjusted for the baseline values of each period and for period effect. 
Compared to the rice-bran diet, the barley beta-glucan diet induced a significant decrease in total and 
LDL-cholesterol concentrations of 0.34 mmol/L (95 % CI: 0.47 to 0.20, p<0.001) and 0.21 mmol/L 
(95 % CI: 0.40 to 0.02, p=0.033), respectively. No effects were observed on other blood lipid 
parameters (HDL-cholesterol, apolipoprotein A-I and B, triglycerides, or various calculated ratios). 
Two animal studies (Delaney et al., 2003; Wilson et al., 2004) were also provided. In the study by 
Delaney et al., (2003), Syrian golden hamsters were fed a hypercholesterolaemic diet for two weeks. 
After this lead-in period, the control hamsters continued to receive the same diet whereas 
experimental hamsters were fed the same diet containing 2, 4 or 8 g beta-glucans from barley or oats 
per 100 g diet at the expense of cellulose, for a total of nine weeks. At weeks 3, 6 and 9, dose 
dependent decreases in total and LDL-cholesterol concentrations were observed, irrespective of the 
source of the beta-glucans. At week 9, a reduction in liver cholesterol was noted for the hamsters 
consuming the highest dose of oat or barley beta-glucans, as well as an increase in faecal total neutral 
sterols concentrations. A second animal study (Wilson et al., 2004) used the same model and design 
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to compare the effects of low MW barley beta-glucans (ca. 175 kDa) to those of high MW barley 
beta-glucans (ca. 1000 kDa). As compared to the control hamsters, both the low and the high MW 
barley beta-glucans (8 g/100 g diet) equally decreased blood total and LDL-cholesterol 
concentrations, and increased concentrations of faecal total neutral sterols and coprostanol, a 
cholesterol derivative. The Panel notes that in these animal studies no differences were observed 
between the effects of barley and oat beta-glucans on total and LDL-cholesterol concentrations, and 
that the low MW barley beta-glucans exerted similar effects to the high MW barley beta-glucans. The 
Panel considers that these studies are supportive of the claimed effect of barley beta-glucans. 
The cholesterol-lowering effect of barley beta-glucans is considered to depend on increased viscosity 
that reduces the reabsorption of bile acids and increases both the synthesis of bile acids from 
cholesterol as well as the faecal excretion of neutral sterols (Delaney et al., 2003; Wilson et al., 2004). 
Viscosity in the small intestine is determined by the concentration, molecular weight and solubility of 
the barley beta-glucans. Barley beta-glucans may be degraded during the purification and 
manufacturing of foods by factors such as shear, heat and the action of enzymes, and its cholesterol-
lowering effect may be weakened or even disappear. Differences in viscosity are thought to explain, at 
least in part, the large variation between the LDL-cholesterol lowering effects found in individual 
studies (EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2009, 2010). 
In weighing the evidence, the Panel took into account that one meta-analysis including 11 RCTs, and 
one additional RCT, which investigated the effects of barley beta-glucans at doses of at least 3 g/day 
showed a decrease in total and LDL-cholesterol concentrations in both normo- and hyper-
cholesterolaemic subjects, and that the mechanism by which barley beta-glucans could exert the 
claimed effect is biologically plausible and supported by the animal studies provided. 
The Panel concludes that a cause and effect relationship has been established between the 
consumption of barley beta-glucans and the lowering of blood LDL-cholesterol concentrations. 
The Panel could have reached this conclusion without considering the meta-analysis claimed as 
proprietary by the applicant. 
4. Panel’s comments on the proposed wording 
The Panel considers that the following wording reflects the scientific evidence: “Barley beta-glucans 
have been shown to lower/reduce blood cholesterol. High cholesterol is a risk factor in the 
development of coronary heart disease”. 
5. Conditions and restrictions of use 
The Panel considers that at least 3 g of barley beta-glucans should be consumed per day in order to 
obtain the claimed effect. This amount can reasonably be consumed as part of a balanced diet. The 
target population is adults who want to lower their blood cholesterol concentrations. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food constituent, barley beta-glucans, which is the subject of the health claim, is 
sufficiently characterised. 
 The claimed effect is “lowering/reduction of blood cholesterol, which may reduce the risk of 
(coronary) heart disease”. The target population proposed by the applicant is adults with 
normal or mildly elevated blood cholesterol concentrations. Lowering blood LDL-cholesterol 
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concentrations is a beneficial physiological effect by decreasing the risk of coronary heart 
disease. 
 A cause and effect relationship has been established between the consumption of barley 
beta-glucans and the lowering of blood LDL-cholesterol concentrations. 
 The following wording reflects the scientific evidence: “Barley beta-glucans have been shown 
to lower/reduce blood cholesterol. High cholesterol is a risk factor in the development of 
coronary heart disease”. 
 At least 3 g of barley beta-glucans should be consumed per day in order to obtain the claimed 
effect. This amount can reasonably be consumed as part of a balanced diet. The target 
population is adults who want to lower their blood cholesterol concentrations. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on barley beta-glucans and lowering of blood cholesterol and reduced risk of 
(coronary) heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006 (Claim serial No: 
0305_BE). June 2011. Submitted by Cargill Incorporated. 
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GLOSSARY / ABBREVIATIONS 
BMI  Body mass index 
CHD  Coronary heart disease 
CI  Confidence interval 
HDL  High-density lipoprotein 
LDL  Low-density lipoprotein 
MW  Molecular weight 
RCT  Randomised controlled trial 
